ZA201002690B - N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors - Google Patents

N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors

Info

Publication number
ZA201002690B
ZA201002690B ZA2010/02690A ZA201002690A ZA201002690B ZA 201002690 B ZA201002690 B ZA 201002690B ZA 2010/02690 A ZA2010/02690 A ZA 2010/02690A ZA 201002690 A ZA201002690 A ZA 201002690A ZA 201002690 B ZA201002690 B ZA 201002690B
Authority
ZA
South Africa
Prior art keywords
hepatitis
useful
hcv
hydropyrimidines
dioxo
Prior art date
Application number
ZA2010/02690A
Other languages
English (en)
Inventor
Geoff G Z Zhang
John E Hengeveld
Ii Thaddeus S Franczyk
Douglas K Hutchinson
Yaya Liu
Clarence L Maring
John T Randolph
Shuang Chen
Anthony R Haight
David M Barnes
Xiaochun Lou
Rolf Wagner
Dachun Liu
Todd W Rockway
Allan C Krueger
Kent D Stewart
Kenton L Longenecker
Yi Gao
Rodger Henry
Brian J Kotecki
David A Betebenner
Pamela L Donner
John K Pratt
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ZA201002690B publication Critical patent/ZA201002690B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2010/02690A 2007-09-17 2010-04-16 N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors ZA201002690B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97288707P 2007-09-17 2007-09-17
US9679408P 2008-09-13 2008-09-13
PCT/US2008/076594 WO2009039135A1 (en) 2007-09-17 2008-09-17 N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors

Publications (1)

Publication Number Publication Date
ZA201002690B true ZA201002690B (en) 2015-12-23

Family

ID=40091991

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/02690A ZA201002690B (en) 2007-09-17 2010-04-16 N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors

Country Status (14)

Country Link
US (2) US8178548B2 (OSRAM)
EP (3) EP2203430B1 (OSRAM)
JP (1) JP5726527B2 (OSRAM)
CN (3) CN101918369B (OSRAM)
AT (1) ATE512954T1 (OSRAM)
CA (1) CA2699989C (OSRAM)
DK (1) DK2203430T3 (OSRAM)
HR (1) HRP20110632T1 (OSRAM)
MX (1) MX2010002904A (OSRAM)
PL (1) PL2203430T3 (OSRAM)
PT (1) PT2203430E (OSRAM)
RU (1) RU2542099C2 (OSRAM)
WO (1) WO2009039135A1 (OSRAM)
ZA (1) ZA201002690B (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039135A1 (en) * 2007-09-17 2009-03-26 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
IN2012DN05113A (OSRAM) 2007-09-17 2015-10-23 Abbott Lab
WO2009039134A1 (en) 2007-09-17 2009-03-26 Abbott Laboratories Anti-infective pyrimidines and uses thereof
MX2011000656A (es) 2008-07-23 2011-02-23 Hoffmann La Roche Compuestos heterociclicos antiviricos.
CN102164909A (zh) 2008-09-26 2011-08-24 弗·哈夫曼-拉罗切有限公司 用于治疗hcv的吡啶或吡嗪衍生物
WO2010049331A1 (en) 2008-10-30 2010-05-06 F. Hoffmann-La Roche Ag Heterocyclic antiviral arylpyridone derivatives
BRPI0924121A2 (pt) 2008-12-22 2019-09-24 Hoffmann La Roche compostos antivirais heterocíclicos
MX2011008641A (es) 2009-03-06 2011-09-06 Hoffmann La Roche Compuestos heterociclicos antivirales.
CA2753825C (en) * 2009-03-24 2017-10-17 Abbott Laboratories Process for preparing substituted pyrimidine antiviral compound
AU2010240888A1 (en) * 2009-04-25 2011-11-17 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
AU2010264802A1 (en) * 2009-06-24 2012-01-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
KR20120059626A (ko) 2009-09-21 2012-06-08 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
JP2013508425A (ja) 2009-10-30 2013-03-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Bi201335、インターフェロンアルファおよびリバビリンを含むhcvの併用療法のための投薬処置計画
BR112012012085A2 (pt) * 2009-11-21 2016-05-17 Hoffmann La Roche compostos antivirais heterocíclicos
US20130029904A1 (en) * 2009-12-18 2013-01-31 Boehringer Ingelheim International Gmbh Hcv combination therapy
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
WO2012004212A1 (en) * 2010-07-07 2012-01-12 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US8841487B2 (en) 2010-07-16 2014-09-23 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
CR20180412A (es) 2010-07-16 2018-11-01 Abbvie Ireland Unlimited Co Proceso para preparar compuestos antivirales
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
WO2012129099A1 (en) * 2011-03-18 2012-09-27 Abbott Laboratories Formulations of phenyl uracil compounds
US8989328B2 (en) * 2013-03-14 2015-03-24 Qualcomm Incorporated Systems and methods for serial communication
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
WO2015197028A1 (en) * 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
CA3041331A1 (en) 2016-11-01 2018-05-11 Merck Sharp & Dohme Corp. Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
CN111936498B (zh) 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
WO2021053495A1 (en) * 2019-09-16 2021-03-25 Novartis Ag Bifunctional degraders and their methods of use
CN114424227B (zh) 2019-09-16 2025-10-21 维萨国际服务协会 用于验证卡图像的系统、方法和计算机程序产品
EP3819006A1 (en) 2019-11-05 2021-05-12 Technische Universität Dresden Compounds with thymine skeleton for use in medicine
CN111018910A (zh) * 2019-12-05 2020-04-17 上海应用技术大学 一种铜催化合成含芳环α-羟基膦酸酯的方法
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
AU627906B2 (en) * 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5084084A (en) * 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5162326A (en) * 1990-02-15 1992-11-10 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
NL9001075A (OSRAM) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
JP3824935B2 (ja) 1999-12-06 2006-09-20 エフ.ホフマン−ラ ロシュ アーゲー 4−ピリミジニル−n−アシル−l−フェニルアラニン
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
IL167957A (en) * 2000-02-04 2009-07-20 Sumitomo Chemical Co Hydroxypyridine compounds
RU2264395C2 (ru) * 2000-02-04 2005-11-20 Сумитомо Кемикал Компани, Лимитед Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 C형 간염 바이러스의 억제제
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
WO2009039134A1 (en) 2007-09-17 2009-03-26 Abbott Laboratories Anti-infective pyrimidines and uses thereof
IN2012DN05113A (OSRAM) 2007-09-17 2015-10-23 Abbott Lab
WO2009039135A1 (en) * 2007-09-17 2009-03-26 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
MX2011000656A (es) 2008-07-23 2011-02-23 Hoffmann La Roche Compuestos heterociclicos antiviricos.

Also Published As

Publication number Publication date
PT2203430E (pt) 2011-09-02
EP2203430A1 (en) 2010-07-07
WO2009039135A1 (en) 2009-03-26
DK2203430T3 (da) 2011-09-26
US8986740B2 (en) 2015-03-24
MX2010002904A (es) 2010-06-02
CA2699989A1 (en) 2009-03-26
EP2548873A1 (en) 2013-01-23
CN101918369A (zh) 2010-12-15
HRP20110632T1 (hr) 2011-10-31
CN105294569A (zh) 2016-02-03
CN105693626A (zh) 2016-06-22
JP5726527B2 (ja) 2015-06-03
US8178548B2 (en) 2012-05-15
PL2203430T3 (pl) 2011-12-30
RU2010114826A (ru) 2011-10-27
EP2203430B1 (en) 2011-06-15
US20120189580A1 (en) 2012-07-26
HK1145839A1 (en) 2011-05-06
CN101918369B (zh) 2016-02-24
EP2377854A1 (en) 2011-10-19
RU2542099C2 (ru) 2015-02-20
US20090176784A1 (en) 2009-07-09
ATE512954T1 (de) 2011-07-15
CA2699989C (en) 2014-03-25
JP2010539188A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
ZA201002690B (en) N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
UA100840C2 (ru) Композиция для лечения вирусного гепатита
MX2009004943A (es) Inhibidores del virus de la hepatitis c.
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
BR112013020042A2 (pt) inibidores de vírus da hepatite c
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
SI1987038T1 (sl) Hcv ns5b inhibitorji
NZ595186A (en) Di-pyrazolidinyl-biphenylyl compounds for treating hepatitis C virus (HCV) infection
MX2012000959A (es) Inhibidores de los virus flaviviridae.
WO2008021936A3 (en) Hepatitis c virus inhibitors
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
ATE547103T1 (de) Hemmer des hepatitis-c-virus
IN2012DN01855A (OSRAM)
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
TW200745004A (en) Novel compounds, their preparation and use
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c